ORENCIA 250 mg powder for concentrate for solution for infusion
Sponsors
University Of Minnesota, Dr Reddy's Laboratories Limited, Universitaetsklinikum Erlangen AöR, IRCCS Istituto Giannina Gaslini, Aalborg University Hospital, Aalborg University Hospital
Conditions
COVID-19Juvenile idiopathic arthritisPsoriatic arthritisRheumatoid ArthritisRheumatoid arthritis
Phase 3
A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
RecruitingCTIS2023-508251-39-00
Start: 2020-09-18Target: 370Updated: 2026-01-20
A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Immune Modulation Strategy Trial
CompletedCTIS2023-504487-41-00
Start: 2023-11-28End: 2025-08-11Target: 345Updated: 2025-05-09
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
CompletedCTIS2023-506664-14-00
Start: 2024-10-24End: 2025-12-02Target: 415Updated: 2025-11-11
Phase 4
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.
RecruitingCTIS2024-514732-24-00
Start: 2025-04-28Target: 328Updated: 2025-08-26
Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
Not yet recruitingCTIS2026-525221-21-01
Target: 180Updated: 2026-07-06